Latest Regulatory Risks News

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

The Australian Competition and Consumer Commission has given the green light to Caterpillar’s proposed acquisition of RPMGlobal, clearing a major regulatory hurdle. The deal now awaits shareholder and Foreign Investment Review Board approvals.

Magellan Asset Management has launched the Magellan Infrastructure Fund (Currency Hedged), an actively managed ETF trading on the ASX under ticker MICH, targeting global listed infrastructure with currency hedging and ESG integration.

Somerset Minerals Limited has launched a C$2.25 million flow-through share offer targeting Canadian investors, aiming to accelerate exploration activities at its Jura project. The capital raise complements a planned institutional placement and highlights both growth ambitions and inherent risks.

Ampol Limited has launched a A$500 million delayed-draw subordinated notes facility, designed to fund its proposed acquisition of EG Australia and refinance existing debt, offering long-term capital with flexible issuance options.

Emyria Limited is scaling up its Perth Empax clinic with increased therapist approvals and treatment rooms, setting the stage for broader national clinical growth next year.

FireFly Metals has launched a dual capital raising initiative, combining a $5 million Share Purchase Plan for eligible shareholders and a C$15 million Canadian flow-through share offer, aimed at funding key development and exploration activities at its Green Bay Copper-Gold Project.

NH3 Clean Energy progresses its WAH2 Project through the FEED phase while forging a pivotal MoU with Japanese giant ITOCHU Corporation to develop clean ammonia bunkering in the Asia Pacific region by 2030.

Lifestyle Communities is extending an option for existing homeowners to adopt a revised Deferred Management Fee model following a pivotal VCAT ruling, aiming to enhance transparency and goodwill regardless of the appeal outcome.

Argenica Therapeutics has demonstrated that its lead drug candidate ARG-007 does not interfere with the clot-busting agent tenecteplase, fulfilling a critical FDA requirement and advancing its stroke therapy development.

Critica Limited has produced a second high-grade rare earth product from its Jupiter Project, achieving 86% total rare earth oxide and confirming the repeatability of its beneficiation process. This milestone reinforces Jupiter's status as Australia's premier rare earth resource amid growing global supply chain concerns.